Intra-arterial Chemoradiation for Oral Cavity Cancer
Author Information
Author(s): Ilana Doweck, K Thomas Robbins, Sandeep Samant, Francisco Vieira
Primary Institution: University of Tennessee, College of Medicine
Hypothesis
There are no significant differences in treatment outcomes based on site for patients receiving RADPLAT for T3-4 carcinoma of the oral cavity, oropharynx, and hypopharynx.
Conclusion
Patients with locally advanced oral cavity cancer treated with the chemoradiation protocol RADPLAT have outcomes that are equal or better compared to patients with similar disease involving the oropharynx and hypopharynx.
Supporting Evidence
- Local disease control was 69% for oral cavity cancer, compared to 86% for oropharyngeal and 79% for hypopharyngeal cancers.
- The overall survival rate for oral cavity cancer was 37%, while it was 41% for oropharyngeal and 6% for hypopharyngeal cancers.
- Mucositis was the most common grade III-IV toxicity, affecting 36% of oral cavity cancer patients.
Takeaway
Doctors are trying a new way to treat mouth cancer that might work just as well as surgery, helping patients keep their ability to eat and talk.
Methodology
A subset analysis of 155 patients with T3-T4 SCC treated with the RADPLAT protocol was performed, comparing outcomes with oropharyngeal and hypopharyngeal carcinoma.
Limitations
The study did not systematically evaluate functional outcomes such as swallowing and speech.
Participant Demographics
Mean age was 58 years, with 18 males and 4 females in the oral cavity group.
Statistical Information
P-Value
0.026
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website